274-83-9

Usage

Uses

Used in Pharmaceutical Applications:
1,2,4-Triazolo[4,3-b]pyridazine is used as a ligand for metal complexes, which can enhance the stability and bioavailability of metal-based drugs. Its unique structure allows for the development of new pharmaceutical agents with improved therapeutic properties.
1,2,4-Triazolo[4,3-b]pyridazine is also used as a building block in organic synthesis, enabling the creation of novel compounds with potential medicinal applications. Its versatile chemical properties facilitate the synthesis of a wide range of biologically active molecules.
Used in Drug Development:
1,2,4-Triazolo[4,3-b]pyridazine is used as a potential drug candidate due to its anti-tumor and anti-inflammatory properties. Its ability to modulate various biological pathways makes it a promising agent for the treatment of various diseases, including cancer and inflammatory disorders.
Used in Industrial Applications:
1,2,4-Triazolo[4,3-b]pyridazine is used as a corrosion inhibitor in various industries. Its ability to protect materials from corrosion extends the lifespan of equipment and infrastructure, reducing maintenance costs and improving overall efficiency.

Upstream product

• 40972-16-5 3-hydrazinyl pyridazine 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 50357-95-4 7,8-dihydro-s-triazolo<4,3-b>pyridazine 
• 73453-19-7 8-Cyclohexyl-[1,2,4]triazolo[4,3-b]pyridazine 
• 73453-24-4 7-Cyclohexyl-[1,2,4]triazolo[4,3-b]pyridazine 
• 73453-25-5 7-Benzyl-[1,2,4]triazolo[4,3-b]pyridazine 
• 73453-20-0 8-Benzyl-[1,2,4]triazolo[4,3-b]pyridazine 
• 87841-07-4 <1,2,4>triazolo<4,3-b>pyridazine-3-aldehyde 

Relevant academic research and scientific papers

Metal free [4+1] and [5+1] annulation reactions to prepare heterocycles using DMF and its derivatives as one-carbon source

1,2,4-Triazolo[3,4-a]pyridines and related heterocycles and substituted triazines were commonly discovered scaffolds in a variety of pharmaceutical and agrochemical agents. Herein, we report a highly efficient and practical method using DMF and its derivative for the [4+1] and [5+1] annulation reactions to prepare these heterocycles. This metal free reaction takes advantages of shelf stable DMF as solvent and carbon donor, imidazole chloride as a catalyst, the mild reaction condition tolerates a broad substrate range and substitutes. The prepared 3-unsubstituted 1,2,4-triazolo[3,4-a]pyridine and derivatives allow further introduction of a variety of functional group1 at 3-position.

PROTEIN KINASE INHIBITORS (VARIANTS), USE THEREOF IN TREATING ONCOLOGICAL DISEASES AND A PHARMACEUTICAL COMPOSITION BASED THEREON

The present invention relates to the treatment of oncological, chronic inflammatory and similar diseases with the aid of new families of chemical compounds having improved efficiency with regard to the inhibition of Abl kinase and mutant forms thereof, as well as other therapeutically significant kinases. It describes protein kinase inhibitors in the form of compounds of general formula (I) and compounds of general formula (II), or a tautomer, an individual isomer, a mixture of isomers, a pharmaceutically acceptable salt, a solvate or a hydrate thereof.

Synthesis of [1,2,4]triazolo[4,3-b]pyridazine-3-carboxylic acids

The first synthesis of 6-substituted-[1,2,4]triazolo[4,3-b]pyridazine-3-carboxylic acids 2a-c was carried out by an enzymatic hydrolysis of alkyl 6-substituted-[1,2,4]triazolo[4,3-b]pyridazine-3-carboxylates 1 by α-chymotrypsin (EC 3.4.21.1) immobilized on a polyacrylamide-type bead support (ACRYLEX C-100). Earlier the synthesis of these compounds failed owing to ready decarboxylation of the products. During enzymatic hydrolysis decarboxylation was only a side reaction.